Just as predicted, they have been trying to pump the stock and then sell more shares. However, I never expected the pricing for this offer was such low at $6.5 per share which reflected the real price of this stock. This company has a long way to go before we see any promising data or milestone.
Sentiment: Strong Sell
I sensed something wrong here. It looks like there was a local tolerability issue with this drug since they just emphasized it did not have significantly systemic clinical AEs. The drug had some local irritation problem before.
I have to agree with you. Not sure when they will start oral Phase 3 program for CABP which will take a long time to enroll. In addition, I guess they are struggling ondevelopment of IV formulatiom for step-down therapy. CEO was taking a lot but she has to show something for real. No near term milestone and not enough cash for Phase 3. Insdiers will start dumping the shares soon. I would consider one of top stocks in my shorting list.
Sentiment: Strong Sell
If you were carefully looking at both safety and efficacy data, this drug had many issues in both safety and efficacy data.
The drug showed safety problems after just a five day short course. In reality, some of those patients do require at least 7 day treatment One drug-related SAE and discountinuation due to hypertension indicated that the drug has serious systemic toxicity.
In terms of the efficacy, it is a very funny way to report the data like this. They should have shown clinical efficacy at Day 7 and 28 using clinical evaluable population (FDA recommended primary endpoint for this indication). In addition, we don't know what's % of clinical evaluation population. There were many discountinuations in middle and high dose groups. All of those patients have to be considered as failure.
The company has tried very hard to keep this program flow. It will be interesting to see how they are going to progress this program to Phase 3.
Investors should get out of this stock before too late.
This is a real horrible company. The stock is depressed. They don't know how to do the PR. At the same time, they rewarded executives more stock. Those guys should be fined. I gues a dramatic surgery is needed.
I think the drop of price represents an excellent opportunity for long, especially at this low volume. Peoples are trying to reposition for next run while some folks were taking profits after approval. Good luck!
There is no question aout this.
Considering current market cap and cash position, it will be an excellent candiate for potential MA. With very solid P3 data for two big indications, this can be something > $1.2 B. It is a perfect time to accumulate this after selling after news.
I have been searching for a good staff to buy. Finally I found this one. Expect to 50% return within 6 months.
Thanks for those shorts.
Although ISIS is trying to emphasize there was no hepatic toxicity issue, it remains a major concern. The sample size is too small to conclude that it was not issue. Four subjects out of eight means 50%. There were a lot of dead drugs due to hepatic toxicity. It is a long way to go before we can see whether it is a safe drug.